Clinical trials: Postmenopausal Osteopenia
Breast Cancer, Menopause
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal women with early-stage breast cancer. This treatment induces bone loss and a higher risk of fractures.
- Conditions
- Breast Cancer, Menopause, Osteopenia
- Trial name
- RISAROS (NCT00859703)
- Testing
- Risedronate
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Low Bone Mass
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
- Trial name
- NCT06250283
- Testing
- Resveratrol
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Osteoporosis
Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss
The purpose of this study is to determine whether soy isoflavone supplementation is safe and effective to prevent bone loss in postmenopausal women.
- Trial name
- OPUS (NCT00665860)
- Testing
- Soy isoflavones
- Where
- 3 sites in United States
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
OSTEOPOROSIS, POSTMENOPAUSAL
Risedronate in Postmenopausal Women With Low Bone Density
The primary objective of this pilot study is to estimate the percent change from baseline at Week 4, Month 6 in NTX bone turnover marker for a monthly 150mg dose of risedronate administered for 6 months and a loading dose regimen…
- Trial name
- NCT00351091
- Testing
- RISEDRONATE
- Volunteers
- 150 people
- Sponsor
- Sanofi
Periodontitis
Impact of SRP on Bone Resorption and Systemic Inflammatory Markers in Postmenopausal Women With Periodontitis
This study is designed to determine the effect of treating postmenopausal women and using non-surgical techniques on biomarkers of systemic inflammation (IL-6 ) and systemic bone resorption (C-terminal collagen cross-links, CTX).
- Trial name
- NCT04261491
- Testing
- scaling and root planing
- Where
- 2 sites in India
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Osteopenia
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture.
- Trial name
- NCT01292187
- Testing
- Oral calcitonin at dinnertime, Oral calcitonin at bedtime
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Tarsa Therapeutics, Inc.
Postmenopausal Osteoporosis, Gut Microbiome
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.
- Conditions
- Postmenopausal Osteoporosis, Gut Microbiome, Menopause
- Trial name
- NCT07365514
- Testing
- Blackcurrant (BC) extract
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Osteoporosis, Atypical Femoral Fracture
Fracture (FX) Improvement With Teriparatide: FiX-IT Study
This open label comparison study examines the hypothesis that teriparatide given immediately following repair of an atypical subtrochanteric or diaphyseal femoral shaft fracture will enhance healing and improve bone mineral…
- Trial name
- FiX-IT (NCT01705587)
- Testing
- teriparatide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Susan L. Greenspan
Osteoporosis, Postmenopausal
Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss
Postmenopausal osteoporosis is one of the important medical disorders affecting women after menopause. It is characterized by bone loss and reduced bone strength. In turn, this leads to increased risk of fracture.
- Trial name
- NCT04609189
- Testing
- Pearlium/EffectiCal, Calcium carbonate/vitamin D3
- Volunteers
- 97 people
- Sponsor
- University of Alberta
Osteoporosis
Osteoporosis Screening Trial
Osteoporosis is the most common disease of bone and characterized firstly by low bone mass and secondly, impaired bone microarchitecture structure resulting in reduced strength and increased risk of fracture.
- Trial name
- OSTRIA (NCT01677637)
- Where
- Greece
- Volunteers
- 5,500 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Postmenopausal, Osteopenia
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone…
- Trial name
- NCT01825785
- Testing
- Romosozumab
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Breast Cancer, Osteoporosis
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.
- Trial name
- NCT00369850
- Testing
- laboratory biomarker analysis, Dual energy X-ray absorptiometry (DEXA), Spine X-ray
- Where
- 16 sites in Australia, France and 6 more
- Volunteers
- 458 people
- Sponsor
- ETOP IBCSG Partners Foundation
Osteoporosis, Osteopenia, Postmenopausal Osteoporosis
Moringa Oleifera on Bone Density
The purpose of this study is to determine the effects of Moringa Oleifera on the structure and function of bone in post-menopausal women ingesting 1000 mg of Moringa Oleifera daily for 12 weeks.
- Trial name
- NCT03026660
- Testing
- Moringa Oleifera
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Appalachian State University
Osteopenia, Bone Disease, Metabolic
Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia
The purpose of this study is to investigate whether the use of alkali compounds, i.e. potassium citrate (K3C6H5O7, hereinafter KCitr) is effective in preventing the progression of osteopenia.
- Trial name
- ACAROS (NCT02731820)
- Testing
- Potassium citrate, Vitamin D3, Calcium carbonate
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Ortopedico Rizzoli
Perimenopausal Bone Loss
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate…
- Trial name
- NCT00221312
- Testing
- Fosamax
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Osteopenia
The Erlangen Fitness and Prevention Study (EFOPS).
The study determines the long-term effect of exercise on osteoporotic fracture risk. Since actually no controlled supervised exercise study exceeds the time frame of 4 years, knowledge concerning the long-term effect of exercise…
- Conditions
- Osteoporosis, Osteopenia, Early Postmenopause
- Trial name
- EFOPS (NCT01177761)
- Testing
- physical exercise
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Menopause, Osteopenia
Third Year Evaluation on Genistein Efficacy and Safety
BACKGROUND: Recent evidences showed that the phytoestrogen genistein positively affects bone metabolism with no clinically significant adverse effects in a cohort of osteopenic, postmenopausal women.
- Trial name
- NCT00626769
- Testing
- aglycone genistein
- Volunteers
- 138 people
- Sponsor
- University of Messina
Postmenopausal Bone Loss, Breast Cancer
A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
The main purpose of this study is to see what levels of Bone Mineral Density post-menopausal women with breast cancer have, and to see if the level of Bone Mineral Density changes during a women's treatment after her surgery.
- Trial name
- NCT00399321
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan Rogel Cancer Center